<DOC>
	<DOC>NCT00111436</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of long-term administration of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies. This study will also evaluate the maintenance of the efficacy of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies. All subjects enrolled in this study will receive 50 mg once weekly or twice weekly (if qualified after week 12) by subcutaneous injections for at least 48 weeks and up to 72 weeks.</brief_summary>
	<brief_title>Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects who were randomized and received at least one dose of investigational product in Study 20021639 or 20021642 (provided that they meet all inclusion/exclusion criteria of this protocol) Active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit Pregnant or breastfeeding females Evidence of skin conditions at the time of the screening visit (e.g., eczema) that would interfere with evaluations of the effect of the investigational product on psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Psoriasis, adults, skin</keyword>
	<keyword>Phase 3, clinical trial</keyword>
	<keyword>Amgen, etanercept</keyword>
	<keyword>EnbrelÂ®, moderate</keyword>
	<keyword>severe, extension</keyword>
</DOC>